|
|
|
|
||
IDRA management should step down..votingAttn: IDRA Management ------------------------------- Vote Yes/NO: if you think that the current IDRA management is responsible for mismanaging the company and the following executives should depart immediately (Robert Doody-must ,Vincent Milano, Clayton Fletcher and Jonathan Yingling). Below are the list of few points: 1.failed merger 2. didn't plan 2125 properly ( why ph-3 for melanoma ? instead should have focused other solid tumors long before like other players) 3. no experience to work with wall street- always on the wrong side of the boat when it comes to raise capital 4. why closed the lab without spending little more efforts on fixing 3GA, why let go Sudhir and bring this incapable CSO ,Jonathan Yingling (who has not produced anything since the time joined the company) 5. why didn't they collaborate with others companies without upfront cash , at least we would have known if TILSO is real deal or not by now with the all the data available. Now, it is too late in the game with Abbvie. 6. Simply false promise of bringing upfront payment deal..where is it ????? 7. last but not least, ****It doesn't take more that one and half years to find some rare disease asset, if you can't then why to keep mentioning in each conference. Market has no mercy for these kind of false promises. .. 8. Bob is a 100% waste of .21cents SP company..why to waste investors money for a IR person who does nothing but bullshitting. Please vote only Yes/NO , reasoning optional . |
return to message board, top of board |